IBD98-M (Ulcerative Colitis)
IBD98-M is an oral, multi-layer coated pellet combines HA and mesalamine for targeted colonic delivery.
• Mode of Action: Forms a resorbable HA barrier over inflamed mucosa while delivering mesalamine locally
• Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation
Inflammatory bowel diseases (IBD), which consists of ulcerative colitis (UC) and Crohn's disease (CD), is are characterized by chronic inflammation of the gastrointestinal tract in genetically susceptible individuals exposed to environmental risk factors that affect 5 million people worldwide.
IBD98-M, a Delayed-Release Capsule, containing mesalamine, and sodium hyaluronate, is being developed by HylMusa™ platform as a combination therapy for treatment of patients with mild to moderate UC. The mechanisms of action of IBD98-M Delayed-Release Capsule is as a combination therapy are to combine the therapeutic effects of mesalamine and a barrier effect of sodium hyaluronate to protect the damaged mucosa. Mesalamine has been widely utilized for decades as an anti-inflammatory agent, in treating mild to moderate active CD and UC. Sodium hyaluronate may act as a protective barrier to the lining of the colon affected by UC, and therefore provides additional therapeutic benefits either by enhancing the efficacy of mesalamine or allowing a reduction of mesalamine dose and its associated toxicity.